Fathom Therapeutics Closes $55M Series A to Push AI Drug Discovery

Fathom Therapeutics has raised an oversubscribed $55 million Series A led by Sutter Hill Ventures to bankroll its AI- and physics-driven platform for small-molecule drug discovery. Kos Biotechnology Partners joined the round through its inaugural Kos BioVentures fund, investing alongside other backers of the company's computational approach.

The financing lands at a moment when pharma productivity has become an investor thesis in itself. Kos, which manages roughly $125 million in assets from New York and Athens, built its case on a simple premise: better modeling means better drugs, faster.

What does the money fund?

The Series A will pay for three things, per the company: expansion of Fathom's technology platform, advancement of its internal drug development pipeline, and the build-out of strategic partnerships. Fathom said it intends to use its platform to evaluate molecular targets and accelerate identification of promising compounds, translating computational discoveries into potential medicines.

How does the platform work?

Fathom's core asset is Microcosmos, a proprietary platform combining quantum chemistry, molecular simulations, and artificial intelligence. The technology models how proteins move and how they interact with potential drug molecules at atomic resolution.

That matters because a protein's behavior and its relationship with a candidate compound can determine how well a medicine works. Traditional discovery can demand extensive laboratory experimentation to find promising molecules and test them against biological targets. Fathom's computational models evaluate molecular behavior instead, targeting interactions that conventional methods struggle to characterize. The company believes the approach opens the door to biological targets that have historically resisted small-molecule medicines.

Who is behind Fathom?

Dr. Huafeng Xu, a computational scientist with experience in molecular modeling and drug design technologies, co-founded Fathom and serves as CEO. His co-founders are Chief Technology Officer Dr. Yujie Wu and Chief Computational Scientist Dr. Jesús Izaguirre. The founding team spans computational chemistry, molecular simulation, and therapeutic discovery, and its scientific background includes contributions to the Anton supercomputer and to computational methods used to study protein-drug interactions.

What did the investors say?

Dr. Simos Simeonidis, co-founder and managing partner of Kos Biotechnology Partners, framed the bet in blunt terms. "Fathom Therapeutics possesses industry-leading expertise in two of the most crucial areas in next-generation drug discovery: quantum chemistry and artificial intelligence," he said. "The ability to model molecular interactions with unprecedented speed and precision has the potential to fundamentally change how we discover medicines, particularly against biological targets that have historically been considered undruggable."

His partner, Alex Tzoukas, tied the deal to a broader industry shift. "The next generation of biopharmaceutical innovation will increasingly emerge from the intersection of computational science, AI, and experimental biology," Tzoukas said, citing a platform that "has already demonstrated compelling early results" and arguing that technologies improving discovery productivity and reaching previously inaccessible targets "can create significant value for patients and investors alike."

Xu kept his statement short and operational: "We welcome Simos, Alex and the deeply experienced Kos team to our syndicate of investors, and we are looking forward to working with them as we push forward with our mission to develop innovative therapeutics."

Why did Kos write the check?

Kos, founded by Simeonidis and Tzoukas, focuses on biotechnology companies and technologies that could yield new therapeutic approaches. The firm invests in therapeutic development, biodefense, and technology-enabled pharmaceutical services. It identified the combination of quantum chemistry and AI as a significant opportunity to improve the productivity of pharmaceutical research, and the Fathom stake expands its portfolio of companies applying advanced computational science to drug research.

The $55 million gives Fathom runway to prove that atomic-resolution simulation can do more than accelerate screening — that it can genuinely unlock targets long written off as undruggable. That proof point, not the model itself, will decide whether the platform converts computing power into marketed medicines.